“WuXi AppTec is delighted to partner with Wugen to help make these life-saving cancer treatments less challenging to produce and more accessible to patients in need.”
Jan 1, 2022 | wuxiapptec.comWuXi Biologics (HK; 2269) and WuXi AppTec ( OTCPK:WUXIF )( OTCPK:WUXAY ) (SHA: 603259) announced that each company would invest $1.4 billion over ten years to build R&D and manufacturing facilities in Singapore.
Jan 1, 2022 | seekingalpha.comAt PepGen, WuXi AppTec is developing its EDO platform to address these critical challenges by optimizing the tissue penetration, cellular uptake and nuclear delivery of oligonucleotides.
Jan 1, 2022 | wuxiapptec.comWuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, today announced a plan to build a new R&D and manufacturing site in Singapore.
Jul 17, 2022 | asiamanufacturingnewstoday.comAnd WuXi AppTec recently announced a $1.4 billion, 10-year project to build a research and manufacturing facility in Singapore.
Aug 24, 2022 | acs.orgWuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services for the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, announced that it is a recipient of the 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan, a global research & consulting firm that helps customers accelerate growth.
Nov 29, 2022 | yahoo.com